Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Rosaria Vincenza Giglio, Anca Pantea Stoian, Khalid Al‐Rasadi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4633-4633
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Hyperlipidemia and hypothyroidism
Xin Su, Hua Peng, Xiang Chen, et al.
Clinica Chimica Acta (2022) Vol. 527, pp. 61-70
Closed Access | Times Cited: 75
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, et al.
Journal of Cardiovascular Development and Disease (2025) Vol. 12, Iss. 1, pp. 19-19
Open Access | Times Cited: 2
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper fromthe International Lipid Expert Panel(ILEP)
Peter E. Penson, Éric Bruckert, David Marais, et al.
Journal of Cachexia Sarcopenia and Muscle (2022) Vol. 13, Iss. 3, pp. 1596-1622
Open Access | Times Cited: 57
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, et al.
Metabolites (2022) Vol. 12, Iss. 3, pp. 256-256
Open Access | Times Cited: 32
The Role of Advanced Glycation End Products on Dyslipidemia
Jelena Vekić, Sanja Vujčić, Biljana Bufan, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 77-77
Open Access | Times Cited: 19
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Rosaria Vincenza Giglio, Angelo Maria Patti, Ali A. Rizvi, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 291-291
Open Access | Times Cited: 19
Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
Angelo Maria Patti, Rosaria Vincenza Giglio, Alberto Allotta, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1362-1362
Open Access | Times Cited: 17
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
Amy L. McKenzie, Shaminie J. Athinarayanan
Diabetes Therapy (2024) Vol. 15, Iss. 4, pp. 843-853
Open Access | Times Cited: 7
Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes
Zongyi Wu, Wei Deng, Yiming Ye, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Walter Masson, Martín Lobo, Juan Patricio Nogueira, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
Dandan Xie, Yutong Li, Murong Xu, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 24
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
Guillaume Mahé, Victor Aboyans, E. Cosson, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Relevance of Lipoprotein Composition in Endothelial Dysfunction and the Development of Hypertension
Lisette Monsibaez Ramírez-Melo, Diego Estrada-Luna, María Esther Rubio-Ruíz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1125-1125
Open Access
The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
Zeki Doğan, Abdülhalim Şenyiğit, Sinem Durmuş, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials
Fernando Garagoli, Walter Masson, Leandro Barbagelata, et al.
Endocrinología Diabetes y Nutrición (2025), pp. 501562-501562
Closed Access
Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
Jingyi Guo, Maoying Wei, Wen‐Hua Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE−/− mice
Yanlong Zhao, Ning Liu, Jifeng Zhang, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials
Hazem Mohamed Salamah, Ahmed Marey, Mohamed Abugdida, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Sultan A. Alfawaz, Abdulhadi S. Burzangi, Ahmed Esmat
Cureus (2024)
Open Access | Times Cited: 3
The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
Alessandro Pezzoli, Ludovico Abenavoli, Marialaura Scarcella, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 387-387
Open Access
The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions
Toka Elemary, Mina Nicola, Mohamed E. A. Abdelrahim, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
New insights into the pathological development of dyslipidemia in patients with hypothyroidism
Xin Su, Xiang Chen, Hua Peng, et al.
Bosnian Journal of Basic Medical Sciences (2021)
Open Access | Times Cited: 16
Comparative Analysis of Biomarkers in Type 2 Diabetes Patients With and Without Comorbidities: Insights Into the Role of Hypertension and Cardiovascular Disease
Symeon Savvopoulos, Haralampos Hatzikirou, Herbert F. Jelinek
Biomarker Insights (2024) Vol. 19
Open Access | Times Cited: 2
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
Teodor Salmen, Claudia-Gabriela Potcovaru, Cristina Bică, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1322-1322
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top